XADAGO (Seqirus Pty Ltd)
Product name
XADAGO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
241 working days (255)
Active ingredients
safinamide mesilate
Registration type
NCE/NBE
Indication
XADAGO (film coated tablets) is indicated for the treatment of adult patients with fluctuating idiopathic Parkinson's disease (PD) as add-on therapy to a regimen that includes levodopa (L-Dopa).